Data gathered: February 23
AI Stock Analysis - Regeneron (REGN)
Analysis generated January 27, 2025. Powered by Chat GPT.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company focused on the discovery, development, manufacturing, and commercialization of pharmaceuticals. Regeneron is well-known for its innovative approach to drug development, leveraging genetics to identify new and effective therapies for various diseases. The company has a robust pipeline of drugs and collaborative relationships with other industry giants.
Stock Alerts - Regeneron (REGN)
 |
Regeneron | February 13 Julie Johnson (member of U.S. congress) is buying shares |
|
Regeneron | February 11 Josh Gottheimer (member of U.S. congress) is selling shares |
|
Regeneron | February 6 AI Score is up by 21.2% in the last couple of days. |
|
Regeneron | February 4 Price is up by 5.1% in the last 24h. |
Alternative Data for Regeneron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 324 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 276,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 54 | Sign up | Sign up | Sign up |
| Patents | 1,391 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 290 | Sign up | Sign up | Sign up |
| Facebook Followers | 18,035 | Sign up | Sign up | Sign up |
| Instagram Followers | 13,964 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 16,144 | Sign up | Sign up | Sign up |
| Twitter Followers | 33,012 | Sign up | Sign up | Sign up |
| Twitter Mentions | 30 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 58 | Sign up | Sign up | Sign up |
| Lobbying Cost | $133,000 | Sign up | Sign up | Sign up |
| Business Outlook | 79 | Sign up | Sign up | Sign up |
| Linkedin Employees | 15,728 | Sign up | Sign up | Sign up |
About Regeneron
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
| Price | $700.33 |
| Target Price | Sign up |
| Volume | 727,330 |
| Market Cap | $76.6B |
| Year Range | $663.02 - $1200.24 |
| Dividend Yield | 0.5% |
| PE Ratio | 18.28 |
| Analyst Rating | 73% buy |
| Industry | Biotechnology |
In the news
ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGNFebruary 23 - GlobeNewswire |
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGNFebruary 20 - Finnhub |
|
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud LawsuitFebruary 20 - Finnhub |
|
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading dayFebruary 20 - MarketWatch |
|
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitFebruary 19 - Finnhub |
|
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNFebruary 19 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 3.79B | 1.06B | 2.73B | 918M | 990M | 12.070 |
| Q3 '24 | 3.72B | 714M | 3.01B | 1.34B | 1.63B | 12.460 |
| Q2 '24 | 3.55B | 759M | 2.79B | 1.43B | 1.21B | 11.560 |
| Q1 '24 | 3.13B | 689M | 2.44B | 722M | 873M | 9.550 |
| Q4 '23 | 3.42B | 947M | 2.47B | 1.16B | 1.12B | 11.860 |
Insider Transactions View All
| McCourt Marion filed to sell 12,931 shares at $844.6. November 5 '24 |
| RYAN ARTHUR F filed to sell 17,678 shares at $1042.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,582 shares at $1059.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,586 shares at $1056.7. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,592 shares at $1053.5. October 3 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Julie Johnson |
Feb 13, 25 | Buy | $1K - $15K |
| Josh Gottheimer |
Feb 11, 25 | Sell | $1K - $15K |
| Jonathan Jackson |
Dec 13, 24 | Sell | $15K - $50K |
Read more about Regeneron (REGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Regeneron?
The Market Cap of Regeneron is $76.6B.
What is Regeneron's PE Ratio?
As of today, Regeneron's PE (Price to Earnings) ratio is 18.28.
What is the current stock price of Regeneron?
Currently, the price of one share of Regeneron stock is $700.33.
How can I analyze the REGN stock price chart for investment decisions?
The REGN stock price chart above provides a comprehensive visual representation of Regeneron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Regeneron shares. Our platform offers an up-to-date REGN stock price chart, along with technical data analysis and alternative data insights.
Does REGN offer dividends to its shareholders?
Yes, Regeneron (REGN) offers dividends to its shareholders, with a dividend yield of 0.5%. This dividend yield represents Regeneron's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Regeneron in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Regeneron?
Some of the similar stocks of Regeneron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.